SFXN3 Antibody

What is SFXN3 and why is it significant in neuroscience research?

SFXN3 (Sideroflexin 3) is a neuronally enriched mitochondrial protein located primarily at synaptic terminals. Its significance stems from its influence on expression levels of neurodegeneration and cell death-associated proteins, including regulators of synaptic degeneration like cysteine string protein α (CSPα) and caspase-3. Research has shown that SFXN3 can affect molecular pathways associated with neurodegenerative diseases including Parkinson's disease (PD) and Alzheimer's disease (AD) . The protein's ability to provide neuroprotection in Drosophila models of PD makes it a promising target for understanding and potentially treating neurodegenerative conditions .

What is the subcellular localization of SFXN3?

SFXN3 is definitively located in the inner mitochondrial membrane. This has been confirmed through several experimental approaches:

• Carbonate extraction experiments showing SFXN3 behaves as a membrane-integral protein

• Swelling and proteinase K protection assays demonstrating SFXN3 follows the same behavior as other inner mitochondrial membrane proteins like CHCHD3 and Mitofilin

• Import pathway studies confirming SFXN3 follows the carrier import pathway for mitochondrial entry

Unlike matrix proteins such as TFAM, SFXN3 is susceptible to proteinase K digestion after mitochondrial swelling, confirming its inner membrane localization rather than matrix placement .

What is the molecular weight and structure of SFXN3?

SFXN3 has a calculated molecular weight of 36 kDa, which is consistent with its observed molecular weight in experimental settings . While it follows the carrier import pathway like metabolite carrier family proteins, SFXN3 does not share their typical 6 transmembrane domain structure. Instead, it is predicted to have either 4 or 5 transmembrane regions, suggesting potential differences in its import and assembly compared to typical carrier proteins .

What validated applications exist for SFXN3 antibodies?

SFXN3 antibodies have been validated for multiple experimental applications as shown in the table below:

Additionally, SFXN3 antibodies have been cited in at least 3 publications for Western Blot applications and 1 publication for IHC applications .

What are the recommended dilutions for SFXN3 antibody applications?

The recommended dilutions for SFXN3 antibody applications vary by technique:

It's important to note that optimal dilutions are sample-dependent, and researchers should titrate the antibody in each testing system to obtain optimal results .

How can I differentiate between SFXN3 and other Sideroflexin family proteins?

This is a significant challenge as antibodies to SFXN3 often show cross-reactivity with other Sfxn homologs. A methodological approach to overcome this limitation is to use in situ hybridization (ISH) techniques:

• Design RNAscope ISH probes targeting multiple short sequences within the SFXN3 transcript to increase specificity

• These probes can specifically recognize SFXN3 transcripts versus other SFXN homologs

• RNAscope ISH has successfully demonstrated SFXN3 expression patterns in retinal tissues, showing labeling mainly in cell bodies of bipolar, amacrine, and retinal ganglion cells, with minimal labeling in the outer nuclear layer and RPE

For protein-level studies, validation using SFXN3-knockout tissues as negative controls is highly recommended to confirm antibody specificity.

What proteins and pathways associated with neurodegeneration are influenced by SFXN3?

High-resolution proteomics on synaptosomes from SFXN3-knockout mice revealed significant changes in proteins associated with neurodegeneration:

• CSPα (cysteine string protein α) levels increased by 28% in SFXN3-KO mice

• Uncleaved Caspase-3 levels decreased by 17.5% in SFXN3-KO mice

• Top canonical pathways affected included oxidative phosphorylation and mitochondrial dysfunction

These findings suggest SFXN3 plays a role in modulating cell death and neurodegenerative processes, potentially through regulating key proteins involved in these pathways.

How does SFXN3 manipulation affect neurodegeneration in model organisms?

Experimental manipulation of SFXN3 has shown significant effects on neurodegeneration:

This indicates SFXN3 may be a potential therapeutic target for neuroprotective strategies, where increasing SFXN3 levels could potentially provide protection against neurodegeneration.

What experimental approaches should be used to study SFXN3's role in synaptic function?

Based on the literature, effective approaches for studying SFXN3's role in synaptic function include:

• Synaptosomal proteomics: Perform TMT mass spectrometry on synaptosomes from wild-type and SFXN3-knockout mice

• Pathway analysis: Use tools like IPA (Ingenuity Pathway Analysis) to identify canonical pathways affected by SFXN3 deficiency

• Validation by immunoblotting: Confirm proteomics findings by immunoblotting for key proteins (e.g., CSPα, Caspase-3)

• In vivo models: Utilize Drosophila models of PD to assess neuroprotective effects of SFXN3 manipulation

• Single-cell RNA sequencing: Identify cell-specific effects of SFXN3 expression or knockout

These approaches provide complementary data on SFXN3's functional roles at different levels of analysis.

What is the significance of SFXN3 expression in cancer, particularly head and neck squamous cell carcinoma (HNSCC)?

Recent research has identified SFXN3 as significantly upregulated in HNSCC tumor tissues compared to normal tissues (P=0.000). Additionally, patients with high SFXN3 expression show poor prognosis, suggesting SFXN3 may serve as a prognostic biomarker in HNSCC .

What experimental methods are recommended to study SFXN3's role in cancer proliferation?

Based on recent HNSCC research, the following methodological approaches are recommended:

• Bioinformatic analysis: Use public databases (TCGA, GEO) to analyze SFXN3 expression patterns and correlations with patient outcomes

• qRT-PCR validation: Verify SFXN3 expression differences between tumor and para-tumor tissues

• Stable knockdown cell lines: Create SFXN3-knockdown cancer cell lines using appropriate vectors

• Live-cell imaging: Use systems like Incucyte to monitor cell proliferation in real-time

• Colony formation assays: Assess long-term proliferative capacity

• Transcriptome sequencing: Perform RNA-seq on knockdown vs. control cells to identify affected pathways

This multi-faceted approach provides comprehensive insights into how SFXN3 influences cancer cell behavior.

How can SFXN3 expression be correlated with therapeutic responses in cancer?

To correlate SFXN3 expression with therapeutic responses:

• Compare SFXN3 expression levels between treatment responders and non-responders using publicly available datasets (e.g., TCGA-HNSCC cohort, GEO cohorts GSE40020, GSE210287)

• Perform pathway enrichment analysis on differentially expressed genes between SFXN3-knockdown and control cells

• Evaluate changes in known drug resistance pathways following SFXN3 manipulation

• Consider combination approaches that target both SFXN3 and related pathways to potentially enhance therapeutic efficacy

What are the critical factors for successful mitochondrial import studies of SFXN3?

Based on detailed mitochondrial import studies, several critical factors should be considered:

• Membrane potential: SFXN3 import depends on membrane potential; experiments should maintain or manipulate this carefully

• Sequential incubation protocols: To study different import stages, use sequential incubations with and without membrane potential

• BN-PAGE analysis: This technique reveals that SFXN3 is less efficient in reaching complete assembly (Stage V) compared to other carrier proteins like AAC

• Import efficiency assessment: SFXN3 may require higher membrane potential or additional insertion components compared to typical carrier proteins

Understanding these factors is crucial for accurately characterizing SFXN3's mitochondrial localization and function.

How can single-cell RNA sequencing data be leveraged for SFXN3 functional studies?

Single-cell RNA sequencing offers powerful insights into SFXN3 function:

• Expression pattern analysis: Identify cell types with high versus low SFXN3 expression (e.g., using normalized expression cutoffs >0.35 for "high" and <0.25 for "low")

• GO pathway enrichment analysis: Compare high- versus low-expressing cells to identify enriched pathways

• Cell-type specific analysis: Perform comparative analyses between specific cell types (e.g., amacrine-8 cells versus other amacrine cells)

• Mitochondrial pathway focus: Specifically examine mitochondrial transport pathways that correlate with SFXN3 expression

• Validation with ISH: Confirm scRNA-seq findings using in situ hybridization to visualize expression patterns in tissues

Research has shown that high-SFXN3-expressing cells are enriched in genes involved in synaptic function, organization, and localization, as well as mitochondrial transport .

What controls are essential when performing immunoblotting for SFXN3?

When conducting immunoblotting for SFXN3, include these essential controls:

• Positive controls: Use tissues/cells known to express SFXN3 (e.g., brain tissue, Neuro-2a cells, SH-SY5Y cells)

• Negative controls: Ideally include SFXN3-knockout samples; if unavailable, use tissues with minimal SFXN3 expression

• Loading controls: Include mitochondrial markers (e.g., VDAC, COX IV) to normalize for mitochondrial content

• Specificity controls: Include samples that might express other SFXN family members to assess cross-reactivity

• Molecular weight verification: Confirm the detected band appears at the expected 36 kDa

These controls ensure reliable and interpretable results when studying SFXN3 protein expression.